In a phase 3 trial of pimavanserin that came to a premature halt for efficacy, patients with dementia-related psychosis who continued the treatment had a lower risk for relapse than those who were ...

Pimavanserin, an atypical antipsychotic, is currently marketed under the brand name Nuplazid ® for the treatment of hallucinations and delusions associated with Parkinson disease psychosis (PDD).

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia. The company said it doesn’t intend ...

The atypical antipsychotic pimavanserin (Nuplazid) reduced the risk of dementia-related psychosis relapse, according to the phase III HARMONY trial. Following an open-label treatment phase to ...

Pimavanserin's potential sales may exceed a billion dollars. I argue that the -020 clinical trial design is excellent for what it is designed to prove or disprove.

Pimavanserin doesn't cure ADP, it attempts to ameliorate the psychosis for the rest of the patient's life. Any pt with ADP has to dose with an antipsychotic the rest of their life.

By week 12, for the overall population there was no significant advantage for pimavanserin versus placebo (treatment difference, −0.51; 95% CI, −2.23 to 1.21; P=0.561). Common adverse events ...

In the 26-week phase II study, people on pimavanserin added to a main antipsychotic saw a significant improvement in the Negative Symptom Assessment-16 (NSA-16) total score (least squares mean -10 ...

Pimavanserin (Nuplazid) initiation among patients with Parkinson disease was associated with greater risk of 30-day hospitalization and mortality up to one year compared with non-users.

Pimavanserin has been approved for use by the Food and Drug Administration (FDA) in the US for this purpose, but has not yet been submitted for approval to the European equivalent, the European ...

Pimavanserin works differently, by blocking a very specific nerve receptor (5HT2A) in the brain.

Pimavanserin has cleared another hurdle on the road to becoming the first antipsychotic approved for use in any neurologic disease. A Food and Drug Administration committee voted 12 to two that the ...